Health Catalyst (HCAT) Tops Q4 EPS by 6c, Offers Guidance

Health Catalyst (NASDAQ: HCAT) reported Q4 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $69.2 million versus the consensus estimate of $68.26 million.

GUIDANCE:

Health Catalyst sees Q1 2023 revenue of $70.3-72.3 million, versus the consensus of $71.6 million.

Health Catalyst sees FY2023 revenue of $290-295 million, versus the consensus of $298.7 million.

For earnings history and earnings-related data on Health Catalyst (HCAT) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Pony AI (PONY) Reports Revenue Above Estimates